Dianthus Therapeutics | MGTA - Current Liabilities


Dianthus Therapeutics reported $28.51M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
Akebia Therapeutics USD 162.35M 1.48M Sep/2026
Alaunos Therapeutics USD 864K 269K Jun/2026
Avita Medical AUD 68.71M 6.04M Jun/2026
Celltrion KRW 288.01B 4.7B Jun/2026
Cspc Pharmaceutical CNY 10.18B 65.36M Dec/2025
Deva Holding AS TRY 6.43B 1.18B Sep/2023
Dianthus Therapeutics USD 28.51M 5.87M Sep/2026
Divis Laboratories Ltd INR 27.07B 6.64B Sep/2026
IQVIA Holdings USD 7.78B 1.04B Sep/2026
Kangmei Pharma CNY 5.1B 280.48M Jun/2026
Knight Therapeutics CAD 165.26M 12.58M Dec/2025
Laboratorios Farma EUR 199.84M 121.75M Dec/2023
Malin Corporation EUR 1000K 500K Dec/2024
Medical Developments International AUD 5.56M 2.26M Dec/2025
Moderna USD 2.03B 506M Sep/2026
Neuren Pharmaceuticals AUD 4.34M 3.58M Dec/2025
Organigram Holdings CAD 107.28M 18.54M Jun/2026
Organon & Co USD 2.65B 36M Sep/2026
Ovoca Bio EUR 1.3M 1.11M Dec/2025
Pharma Mar EUR 125.39M 26.97M Sep/2026
Qiagen NV USD 581.45M 102.34M Jun/2026
Revvity USD 701.48M 574.88M Sep/2026
Sartorius EUR 1.55B 102.8M Sep/2026
Sino Biopharmaceutical CNY 24.85B 5.29B Jun/2025
Tectonic Therapeutic USD 10.37M 2.59M Jun/2026
Tilray USD 259.32M 8.32M Sep/2025
Viatris USD 6.64B 290.7M Sep/2026
Xeris Pharmaceuticals USD 134.48M 55.09M Sep/2026
Zealand Pharma A/S 404M 260.96M Mar/2026
Zz Pientze Pharmaceu CNY 2.74B 277.02M Sep/2026